Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessCompaniesSun Pharma arm to buy Takeda's US-based generics subsidiary

    Sun Pharma arm to buy Takeda's US-based generics subsidiary

    Drug major Sun Pharmaceutical Industries today said its arm Caraco Pharma will buy Japanese drug maker Takeda Pharmaceuticals' US-based generics subsidiary URL Pharma.

    December 18, 2012 / 09:17 IST
       
       
      26 Aug, 2025 12:21
      Volume
      Todays L/H
      More

      Drug major Sun Pharmaceutical Industries today said its arm Caraco Pharma will buy Japanese drug maker Takeda Pharmaceuticals' US-based generics subsidiary URL Pharma.
          
      Caraco Pharmaceutical Laboratories has entered into a definitive agreement with Takeda Pharmaceuticals US Inc, a wholly-owned subsidiary of Takeda Pharmaceutical Co to buy the URL Pharma Inc's generic business, Sun Pharmaceutical Industries said in a statement.


      Also read: Bet on consumption, pharma and pvt banks in '13: Girish Pai


      It, however, remained silent on the financial details of the deal. "Upon completion of the purchase, the non-Colcrys (colchicine, USP) generic assets of URL Pharma will be owned and managed by Caraco," it added.


      The deal is subject to satisfaction of customary closing conditions, including applicable regulatory approvals, Sun Pharma said. URL Pharma is a former privately-held Philadelphia-based pharmaceutical company acquired by Takeda America Holdings, Inc in June, 2012.

      Shares of Sun Pharmaceutical Industries today closed at Rs 720 apiece on the BSE, up 0.47 per cent from their previous close.

      first published: Dec 17, 2012 09:37 pm

      Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

      Subscribe to Tech Newsletters

      • On Saturdays

        Find the best of Al News in one place, specially curated for you every weekend.

      • Daily-Weekdays

        Stay on top of the latest tech trends and biggest startup news.

      Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347